Crystalys Therapeutics secured an additional $130 million to support pivotal tests of its gout drug dotinurad, currently in late-stage pivotal development. Dotinurad is targeting a disease area with limited options for some patients, and Crystalys is positioning the program for outcomes that can support regulatory decision-making. The report also links dotinurad’s mechanism positioning to prior industry moves, including a molecule added to Sobi’s pipeline through a large acquisition. The funding underscores ongoing investor appetite for inflammatory indications where targeted small-molecule competition is intensifying.